Disciplined Growth Investors Decreased Mimedx Group Com (MDXG) Position By $353,925; Bluebird Bio (BLUE) Sentiment Is 1.51

March 8, 2018 - By Ruchi Gupta

Disciplined Growth Investors Inc decreased Mimedx Group Inc Com (MDXG) stake by 4.43% reported in 2017Q3 SEC filing. Disciplined Growth Investors Inc sold 32,175 shares as Mimedx Group Inc Com (MDXG)’s stock rose 72.01%. The Disciplined Growth Investors Inc holds 694,050 shares with $8.25 million value, down from 726,225 last quarter. Mimedx Group Inc Com now has $881.09 million valuation. The stock increased 0.45% or $0.04 during the last trading session, reaching $7.94. About 871,759 shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since March 8, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $11.32 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

Among 9 analysts covering MiMedx Group (NASDAQ:MDXG), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. MiMedx Group had 30 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Aegis Capital on Tuesday, November 8. The firm has “Buy” rating by Needham given on Monday, June 26. Lake Street maintained MiMedx Group, Inc. (NASDAQ:MDXG) rating on Tuesday, April 19. Lake Street has “Buy” rating and $12 target. Needham maintained the stock with “Buy” rating in Wednesday, December 13 report. Needham maintained MiMedx Group, Inc. (NASDAQ:MDXG) rating on Wednesday, October 14. Needham has “Buy” rating and $13 target. As per Thursday, September 21, the company rating was maintained by Piper Jaffray. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) earned “Buy” rating by Needham on Friday, December 1. The rating was maintained by Canaccord Genuity on Friday, December 18 with “Buy”. The rating was downgraded by Needham to “Buy” on Wednesday, July 29. The firm has “Overweight” rating given on Wednesday, January 20 by First Analysis.

Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.96, from 1.97 in 2017Q2. It dived, as 21 investors sold MDXG shares while 44 reduced holdings. 48 funds opened positions while 80 raised stakes. 77.22 million shares or 15.28% more from 66.99 million shares in 2017Q2 were reported. Kestrel Invest Mngmt reported 2.86% in MiMedx Group, Inc. (NASDAQ:MDXG). Northwestern Mutual Wealth stated it has 1,000 shares or 0% of all its holdings. Homrich And Berg has invested 0.02% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Mycio Wealth Prtn Ltd Com invested 0.46% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Amalgamated Savings Bank has invested 0.01% in MiMedx Group, Inc. (NASDAQ:MDXG). Strs Ohio holds 0% or 74,100 shares. Clarivest Asset Mngmt Ltd invested 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Parametric Port has invested 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Millennium Mgmt Ltd Co owns 1.97M shares. State Of Tennessee Treasury Department invested in 0.01% or 87,694 shares. Teachers Retirement Of The State Of Kentucky has invested 0% in MiMedx Group, Inc. (NASDAQ:MDXG). Eqis Cap Management Incorporated holds 0.01% or 17,948 shares in its portfolio. Interest Group holds 81,960 shares. Dupont Management holds 0.02% or 92,307 shares. Hussman Strategic Advisors owns 50,000 shares.

Cormorant Asset Management Llc holds 3.33% of its portfolio in bluebird bio, Inc. for 137,500 shares. Eventide Asset Management Llc owns 412,000 shares or 3.21% of their US portfolio. Moreover, First Light Asset Management Llc has 1.57% invested in the company for 36,085 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 1.03% in the stock. Baillie Gifford & Co, a United Kingdom-based fund reported 5.32 million shares.

The stock increased 0.47% or $1.05 during the last trading session, reaching $226.45. About 429,678 shares traded. bluebird bio, Inc. (BLUE) has risen 112.34% since March 8, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News